Showing 1211-1220 of 1319 results for "".
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Protein Levels in Plasma Highly Predictive of Future Dementia Risk According to UK Biobank Studyhttps://practicalneurology.com/news/protein-levels-in-plasma-highly-predictive-of-future-dementia-risk-according-to-uk-biobank-study/2470405/People with higher baseline plasma levels of certain proteins, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), growth/differentiation factor 15 (GDF15), and latent-transforming growth factor beta-binding protein 2 (LTBP2), had an elevated risk of developing deme
- Phenogroups of Migraine Identified With Artificial Intelligence-Guided Topologic Mappinghttps://practicalneurology.com/news/phenogroups-of-migraine-identified-with-artificial-intelligence-guided-topologic-mapping/2469941/Migraine is increasingly as a as a heterogeneous disorder, with a wide variety of headache characteristics, associated symptoms, and treatment responses. In a study presented at the American Headache Society meeting in Denver, CO June 9-12, 2022, Chia-Chun Chiang, MD, senior assoc
- Erenumab Shown to Have Higher Efficacy and Tolerability Compared With Topiramate for Migrainehttps://practicalneurology.com/news/erenumab-shown-to-have-higher-efficacy-and-tolerability-compared-with-topiramate-for-migraine/2469738/In the HER-MES study (NCT03828539), erenumab (Aimovig; Amgen, Thousand Oaks, CA), a calcitonin gene-related peptide (CGRP) inhibitor, had superior efficacy and tolerability as treatment for adults wit
- Midlife Plasma Levels of Amyloid Beta May Predict Future Dementia or Mild Cognitive Impairmenthttps://practicalneurology.com/news/midlife-plasma-levels-of-amyloid-beta-may-predict-future-dementia-or-mild-cognitive-impairment/2469658/Data from the Arthritis in Communities study (NCT00005131) published in Neurology showed midlife plasma levels of amyloid beta 42 (Aβ
- Antibody–Oligonucleotide Conjugate Shows Target Engagement in Myotonic Dystrophy Type 1https://practicalneurology.com/news/antibodyoligonucleotide-conjugate-shows-target-engagement-in-myotonic-dystrophy-type/2485921/Treatment with delpacibart etedesiran (del-desiran [AOC 1001]; Avidity Biosciences, San Diego, CA), a monoclonal antibody (mAb) oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing biomarkers in adults with myotonic dystrophy type 1 (DM1). These
- Potential Essential Tremor Tx Receives FDA Breakthrough Therapy Designationhttps://practicalneurology.com/news/potential-essential-tremor-tx-receives-fda-breakthrough-therapy-designation/2485146/The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ulixacaltamide (Praxis Precision Medicines, Boston, MA) for the treatment of people with essential tremor (ET). The designation was based on positive topline results from the Essential3 phase 3 clinical trial (
- Promising Data Presented for Investigational Oral Treatment for People with Alzheimer’shttps://practicalneurology.com/news/promising-data-presented-for-investigational-oral-treatment-for-people-with-alzheimers/2484840/Once-daily treatment with tazbentetol (SPG302; Spinogenix, Los Angeles, CA) was associated with rapid and sustained improvements in cognitive and functional measures in a study of adults with mild-to-moderate Alzheimer disease (AD), according to topline results presented at the 18th annual Clinic
- Huntington Disease Progression Significantly Slowed with Investigational Gene Therapyhttps://practicalneurology.com/news/huntington-disease-progression-significantly-slowed-with-investigational-gene-therapy/2483588/AMT-130 (uniQure, Amsterdam, The Netherlands), an investigational gene therapy, was shown to substantially slow disease progression in people with Huntington disease (HD), according to topline results from a phase 1/2 clinical trial program (NCT05243017, NCT04120493). Participants in the program
- FDA Grants Breakthrough Therapy Designation to Delpacibart Zotadirsen for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy/2475932/Del-zota (delpacibart zotadirsen; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational therapy for the treatment of people with Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 ski